Providing a focal point to push industry collaboration through updates on clinical advancements and investment opportunities, SMi presents the established 20th annual Superbugs & Superdrugs conference which will return to Central London on 19th and 20th March 2018.
The threat of AMR is regularly making front page news but what is the industry actually doing? Are drug manufacturers any closer to finding a solution and how is the government helping? These will be just some of the questions answered through powerful keynote addresses delivered by an expert panel of scientific leaders, drug discovery specialists and government bodies such as MHRA and DNDi.
SPEAKERS INCLUDE:
- Richard Bax, Senior Partner, TranScrip Partners
- Lloyd Czaplewski, Dir, Chemical Biology Ventures
- Mair Powell, Senior Clinical Assessor, MHRA
- Jean-Pierre Paccaud, Dir of Business Development at GARDP, Drugs for Neglected Diseases initiative (DNDi)
- Conrad Lichtenstein, CSO, Nemesis Bioscience
- David Brown, MD & Founder, Alchemy Biomedical Consulting
- Domingo Gargallo-Viola, CSO, ABAC Therapeutics
- John George, CSO, Oppilotech
- Larry Sutton, Scientific Founder, Gladius Pharmaceuticals
- Kathy Talkington, Project Dir, Pew Charitable Trusts
- David Cook, CSO, Blueberry Therapeutics
- William Weiss, Dir of Pre-Clinical Services, UNT Health Science Center
- Cara Cassino, CMO, ContraFect
- Stephen Barat, Head of Pre-Clinical & Early Clinical Development, SCYNEXIS
AGENDA HIGHLIGHTS:
- Analyze the current status of antimicrobial resistance with industry led insight into current strategies to tackle AMR
- Hear exclusive case studies from a selection of pharmaceutical companies on clinical progress
- Learn about regulatory pathways for the registration of new antimicrobial agents
- Evaluate the latest incentives and funding solutions to spur drug discovery
- Explore novel alternatives to antibiotics currently in development
Early birds available online
The threat of AMR is regularly making front page news but what is the industry actually doing? Are drug manufacturers any closer to finding a solution and how is the government helping? These will be just some of the questions answered through powerful keynote addresses delivered by an expert panel of scientific leaders, drug discovery specialists and government bodies such as MHRA and DNDi.
SPEAKERS INCLUDE:
- Richard Bax, Senior Partner, TranScrip Partners
- Lloyd Czaplewski, Dir, Chemical Biology Ventures
- Mair Powell, Senior Clinical Assessor, MHRA
- Jean-Pierre Paccaud, Dir of Business Development at GARDP, Drugs for Neglected Diseases initiative (DNDi)
- Conrad Lichtenstein, CSO, Nemesis Bioscience
- David Brown, MD & Founder, Alchemy Biomedical Consulting
- Domingo Gargallo-Viola, CSO, ABAC Therapeutics
- John George, CSO, Oppilotech
- Larry Sutton, Scientific Founder, Gladius Pharmaceuticals
- Kathy Talkington, Project Dir, Pew Charitable Trusts
- David Cook, CSO, Blueberry Therapeutics
- William Weiss, Dir of Pre-Clinical Services, UNT Health Science Center
- Cara Cassino, CMO, ContraFect
- Stephen Barat, Head of Pre-Clinical & Early Clinical Development, SCYNEXIS
AGENDA HIGHLIGHTS:
- Analyze the current status of antimicrobial resistance with industry led insight into current strategies to tackle AMR
- Hear exclusive case studies from a selection of pharmaceutical companies on clinical progress
- Learn about regulatory pathways for the registration of new antimicrobial agents
- Evaluate the latest incentives and funding solutions to spur drug discovery
- Explore novel alternatives to antibiotics currently in development
Early birds available online
